SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rick Costantino who wrote (321)8/25/1996 12:34:00 PM
From: Richard Mazzarella   of 4342
 
Rick, I have 20% of my position in PRLNW (shares, not dollars). I just view them as a long term call options holding while I trade the common. Also, I remember that you had made comments about the high cost of FDA approval before. I though that PRLN did not want to go that route and just found confirmation from text in EDGAR PRLN 10QSB 08/14/96:

<<A portion of the Company's strategy is to develop certain of its
products to a point where its value can be clearly established and then
license marketing and other rights to third parties. To this end, the
Company completes sufficient product development so that prospective
licensees can more readily recognize the value of completing the
product's development and its ultimate commercialization.

In addition, the Company's strategy is to directly market those products
which it believes can be marketed without significant marketing
expenditures and without the time-consuming process of having such
products approved by regulatory agencies such as the Food and Drug
Administration. >>
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext